• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Histogen Inc.

    12/15/23 4:05:05 PM ET
    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HSTO alert in real time by email
    DEFA14A 1 hsto_sm_defa_14a_2.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material under §240.14a-12

    Histogen Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


    Additional Materials for Proxy Statement

    Dated December 15, 2023

    The following supplements our definitive proxy statement filed with the Securities and Exchange Commission on October 18, 2023 relating to the Special Meeting of Stockholders of Histogen Inc., to be held virtually, via live webcast at www.virtualshareholdermeeting.com/HSTO2023SM, on Tuesday, December 5, 2023, at 8:00 a.m., and any adjournments or postponements thereof.

    On or around December 15, 2023, Histogen Inc. (“Histogen”) mailed the letter attached as Exhibit A and a duplicate proxy card to Histogen unvoted objecting beneficial stockholders who held 100 or more shares of Histogen common stock as of October 16, 2023, as well as the top 100 unvoted nonobjecting beneficial stockholders of Histogen common stock as of October 16, 2023.

     

     

     

    /s/ Susan A. Knudson

     

     

    Susan A. Knudson

     

     

    President, Chief Executive Officer, Chief Financial Officer and Secretary

     

     


    Exhibit A

    img17169690_0.jpg 

     

    * * * IMPORTANT REMINDER TO VOTE BEFORE JANARY 4, 2024, THE FINAL DATE TO CONDUCT THE SHAREHOLDER MEETING * * *

     

    * * * POTENTIAL ESTIMATED CASH DISTRIBUTION TO SHAREHOLDERS OF $0.30 TO $0.41 IF DISSOLUTION PROPOSAL 1 APPROVED * * *

     

    Dear Histogen Inc. Stockholder,

    Dear Histogen Inc. Stockholder, By now, you should have received your proxy materials for the 2023 Special Meeting of Stockholders of Histogen Inc., which is scheduled to be held virtually, via live webcast, on Thursday January 4, 2024 at 8:00 a.m., Pacific Time. If you have already voted, we would like to thank you for your vote. There are two proposals scheduled for a vote.

     

    There are two proposals scheduled for a vote:

    •
    Proposal 1: To approve the liquidation and dissolution of the Company pursuant to the Plan of Liquidation and Dissolution (the “Plan of Dissolution”), which, if approved, will authorize the Company to liquidate and dissolve the Company (the “Dissolution”) in accordance with the Plan of Dissolution (the “Dissolution Proposal”).
    •
    Proposal 2: To approve the adjournment from time to time of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes to approve the Plan of Dissolution (the “Adjournment Proposal”).

    Pursuant to the Plan of Dissolution, we intend to liquidate all of Histogen Inc.’s remaining non-cash assets and, after satisfying or making reasonable provision for the satisfaction of claims, obligations and liabilities as required by applicable law, distribute any remaining cash to Histogen Inc. stockholders. We can only estimate the amount of cash that may be available for distribution to stockholders. We estimate that the aggregate amount of cash distributions to stockholders will be in the range of $0.30 and $0.41 per share of common stock, provided, however, that we may not have any available cash for distributions.

    If our stockholders do not approve the Plan of Dissolution, the Board will continue to explore what, if any, alternatives are available for the future of the Company in light of its discontinued business activities; however, those alternatives are likely limited to seeking voluntary dissolution at a later time with potentially diminished assets, seeking bankruptcy protection (should our net assets decline to levels that would require such action).

     

    The Histogen Board of Directors unanimously recommends that you vote (i) “FOR” the Dissolution Proposal; and (ii) “FOR” the Adjournment Proposal. Even if you plan on attending the virtual meeting, we urge you to vote your shares now, so they can be tabulated prior to the meeting.

     

    Stockholders who have any questions or need assistance executing their vote, please contact Kingsdale Advisors, Histogen’s proxy solicitor.

     

    img17169690_1.jpg 

    Website: www.histogenvote.com

    E-mail: [email protected]

    U.S. call 1 888 212 9553

    Outside North America, Banks and Brokers Call Collect: 1-646-741-7961

     

     

    Thank you for your investment in Histogen Inc. and for taking the time to vote your shares.

     

     

     

    Sincerely,

     

     

    img17169690_2.jpg 

     

     

    Susan A. Knudson

     

     

    President, Chief Executive Officer, Chief Financial Officer and Secretary

     


    Get the next $HSTO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSTO

    DatePrice TargetRatingAnalyst
    8/30/2021$2.40Buy
    HC Wainwright & Co.
    More analyst ratings

    $HSTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Histogen Announces Second Adjournment of Special Meeting of Stockholders

      Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO), today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, January 4, 2024 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The Special Meeting, which will be reconvened for a final time on January 4, 2024, will continue to be held v

      12/14/23 4:15:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Announces Adjournment of Special Meeting of Stockholders

      SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO) today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The reconvened Special Meeting on December 14, 2023 will continue to be held via live webcast at www.virtualshareholdermeeting.com/HSTO2023SM. In addition, the record date for determining stockholders entitled to vote at the Special Meeting will remain the close of business on Octob

      12/5/23 4:05:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Announces Board Approval of Complete Liquidation and Dissolution

      SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of Septem

      9/18/23 4:05:04 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Windham-Bannister Susan Richards

      4 - Histogen Inc. (0001383701) (Issuer)

      6/21/23 4:11:05 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Satz Brian

      4 - Histogen Inc. (0001383701) (Issuer)

      6/21/23 4:10:02 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kisner Daniel L

      4 - Histogen Inc. (0001383701) (Issuer)

      6/21/23 4:09:19 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

      SC 13G/A - Histogen Inc. (0001383701) (Subject)

      2/14/23 12:56:27 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

      SC 13G/A - Histogen Inc. (0001383701) (Subject)

      2/8/23 6:07:04 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

      SC 13G/A - Histogen Inc. (0001383701) (Subject)

      2/11/22 7:06:22 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    Leadership Updates

    Live Leadership Updates

    See more
    • Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

      SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer. "We are very excited about Dr. Spada joining our management team.  Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors," said Steven J. Mento Ph.D., Executive Chairman and Interim President and Chief E

      1/3/23 4:05:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

      Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t

      8/8/22 8:45:00 AM ET
      $CVM
      $HSTO
      $TXMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Orhub's Ryan Fernan Becomes Head Of Pur Biologics, Leading Regenerative Therapeutic Efforts

      A proven industry leader and executive, Ryan Fernan, will help ORHub advance Ortho-Spine technology beyond current limitations.IRVINE, CA / ACCESSWIRE / July 27, 2022 / ORHub, Inc. (OTC:ORHB) officially kicks off the acquisition of PUR Biologics ("PUR") with the appointment of Ryan Fernan as the Head of PUR Biologics. An ORHub biotech company, PUR Biologics is focused on delivering next generation regenerative biologic products to address degenerative musculoskeletal diseases.Mr. Fernan, brings direct access to a broad industry network with a proven track record of over 18 years in the medical device and biotechnology industry. Recognized as a frontrunner in sales and product development, Mr

      7/27/22 2:30:00 PM ET
      $BAX
      $HSTO
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $HSTO
    Financials

    Live finance-specific insights

    See more
    • Histogen Reports Year-End 2022 Results and Provides Business Update

      SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments. "Our team is very excited about the new direction of the company. We remain focused on the development of emricasan as a potential treatment for acute bacterial skin and skin structure infections (ABSSSI), including those related to methicillin res

      3/9/23 4:05:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

      SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We remain focused on the feasibility of developing emricasan as a potential treatment for bacterial skin infections including those related to methicillin resistant staphylococcus aureus ("MRSA") and evaluating our caspase-1 inh

      11/10/22 4:15:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update

      Closed $5M Financing in July Regained Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We continue to focus on execution of IND enabling activities for HST 004 in spinal disc regeneration, exploration of testing emricasan in ani

      8/11/22 4:05:00 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Histogen Inc.

      15-12G - Histogen Inc. (0001383701) (Filer)

      1/4/24 1:21:25 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Histogen Inc.

      DEFA14A - Histogen Inc. (0001383701) (Filer)

      12/15/23 4:05:05 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by Histogen Inc.

      425 - Histogen Inc. (0001383701) (Subject)

      12/14/23 4:25:01 PM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HSTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Histogen with a new price target

      HC Wainwright & Co. initiated coverage of Histogen with a rating of Buy and set a new price target of $2.40

      8/30/21 6:17:04 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Histogen with a new price target

      Canaccord Genuity reiterated coverage of Histogen with a rating of Buy and set a new price target of $4.00 from $5.00 previously

      6/4/21 10:01:35 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Histogen with a new price target

      Canaccord Genuity initiated coverage of Histogen with a rating of Buy and set a new price target of $5.00

      3/10/21 8:10:32 AM ET
      $HSTO
      Biotechnology: Pharmaceutical Preparations
      Health Care